Interactions Between Adrenal-regulatory and Calcium-regulatory Hormones in Human Health

Overview

Journal Curr Opin Endocrinol Diabetes Obes

Specialty Endocrinology

Date 2014 Apr 4

PMID 24694551

Citations 22

Authors

Jenifer M Brown

Anand Vaidya

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: To summarize the evidence characterizing the interactions between adrenal-regulating and calcium-regulating hormones, and the relevance of these interactions to human cardiovascular and skeletal health.

Recent Findings: Human studies support the regulation of parathyroid hormone (PTH) by the renin-angiotensin-aldosterone system (RAAS): angiotensin II may stimulate PTH secretion via an acute and direct mechanism, whereas aldosterone may exert a chronic stimulation of PTH secretion. Studies in primary aldosteronism, congestive heart failure, and chronic kidney disease have identified associations between hyperaldosteronism, hyperparathyroidism, and bone loss, which appear to improve when inhibiting the RAAS. Conversely, elevated PTH and insufficient vitamin D status have been associated with adverse cardiovascular outcomes, which may be mediated by the RAAS. Studies of primary hyperparathyroidism implicate PTH-mediated stimulation of the RAAS, and recent evidence shows that the vitamin D-vitamin D receptor complex may negatively regulate renin expression and RAAS activity. Ongoing human interventional studies are evaluating the influence of RAAS inhibition on PTH and the influence of vitamin D receptor agonists on RAAS activity.

Summary: Although previously considered independent endocrine systems, emerging evidence supports a complex web of interactions between adrenal-regulating and calcium-regulating hormones, with implications for human cardiovascular and skeletal health.

Citing Articles

Vitamin D-Parathyroid Hormone-Fibroblast Growth Factor 23 Axis and Cardiac Remodeling.

Deng C, Wu Y Am J Cardiovasc Drugs. 2024; 25(1):25-36.

PMID: 39392562 DOI: 10.1007/s40256-024-00688-8.

Saline suppression testing-induced hypocalcemia and implications for clinical interpretations.

Parksook W, Brown J, Milks J, Tsai L, Chan J, Moore A Eur J Endocrinol. 2024; 191(2):241-250.

PMID: 39073780 PMC: 11322817. DOI: 10.1093/ejendo/lvae099.

Bartter Syndrome Presenting as Arginine-Vasopressin Resistance: A Report of 2 Cases.

Sousa M, Medeiros R, Rodrigues A, Pereira B Am J Case Rep. 2024; 25:e942872.

PMID: 38885190 PMC: 11196210. DOI: 10.12659/AJCR.942872.

Bone and mineral metabolism in patients with primary aldosteronism: A systematic review and meta-analysis.

Wang A, Wang Y, Liu H, Hu X, Li J, Xu H Front Endocrinol (Lausanne). 2022; 13:1027841.

PMID: 36387892 PMC: 9659816. DOI: 10.3389/fendo.2022.1027841.

Evaluating the clinical and mechanistic effects of eplerenone and amiloride monotherapy, and combination therapy with cinacalcet, in primary hyperparathyroidism: A placebo-controlled randomized trial.

Parksook W, Heydarpour M, Brown J, Turchin A, Mannstadt M, Vaidya A Clin Endocrinol (Oxf). 2022; 98(4):516-526.

PMID: 36316798 PMC: 10006290. DOI: 10.1111/cen.14840.

References

Fallo F, Rocco S, Pagotto U, Zangari M, Luisetto G, Mantero F . Aldosterone and pressor responses to angiotensin II in primary hyperparathyroidism. J Hypertens Suppl. 1989; 7(6):S192-3. DOI: 10.1097/00004872-198900076-00092. View

Letizia C, Ferrari P, Cotesta D, Caliumi C, Cianci R, Cerci S . Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J Hum Hypertens. 2005; 19(11):901-6. DOI: 10.1038/sj.jhh.1001907. View

Ceccoli L, Ronconi V, Giovannini L, Marcheggiani M, Turchi F, Boscaro M . Bone health and aldosterone excess. Osteoporos Int. 2013; 24(11):2801-7. DOI: 10.1007/s00198-013-2399-1. View

Kitazawa S, Fukase M, Kitazawa R, Takenaka A, Gotoh A, Fujita T . Immunohistologic evaluation of parathyroid hormone-related protein in human lung cancer and normal tissue with newly developed monoclonal antibody. Cancer. 1991; 67(4):984-9. DOI: 10.1002/1097-0142(19910215)67:4<984::aid-cncr2820670421>3.0.co;2-0. View

Rossi E, Sani C, Perazzoli F, Casoli M, Negro A, Dotti C . Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995; 8(9):884-93. DOI: 10.1016/0895-7061(95)00182-O. View

Lind L, Ridefelt P, Rastad J, Akerstrom G, Ljunghall S . Relationship between abnormal regulation of cytoplasmic calcium and elevated blood pressure in patients with primary hyperparathyroidism. J Hum Hypertens. 1994; 8(2):113-8. View

Maniero C, Fassina A, Seccia T, Toniato A, Iacobone M, Plebani M . Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens. 2011; 30(2):390-5. DOI: 10.1097/HJH.0b013e32834f0451. View

Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm B . Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta. 2010; 411(17-18):1354-60. DOI: 10.1016/j.cca.2010.05.037. View

Vaidya A, Sun B, Larson C, Forman J, Williams J . Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study. J Clin Endocrinol Metab. 2012; 97(7):2456-65. PMC: 3387405. DOI: 10.1210/jc.2012-1156. View

10.

Atchison D, Beierwaltes W . The influence of extracellular and intracellular calcium on the secretion of renin. Pflugers Arch. 2012; 465(1):59-69. PMC: 3553253. DOI: 10.1007/s00424-012-1107-x. View

11.

Yu N, Donnan P, Leese G . A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf). 2010; 75(2):169-76. DOI: 10.1111/j.1365-2265.2010.03958.x. View

12.

Li Y, Kong J, Wei M, Chen Z, Liu S, Cao L . 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110(2):229-38. PMC: 151055. DOI: 10.1172/JCI15219. View

13.

Lee M, Bohm M, Paul M, Ganten D . Tissue renin-angiotensin systems. Their role in cardiovascular disease. Circulation. 1993; 87(5 Suppl):IV7-13. View

14.

Vestergaard P, Mollerup C, Frokjaer V, Christiansen P, Blichert-Toft M, Mosekilde L . Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000; 321(7261):598-602. PMC: 27473. DOI: 10.1136/bmj.321.7261.598. View

15.

Hedback G, Oden A . Increased risk of death from primary hyperparathyroidism--an update. Eur J Clin Invest. 1998; 28(4):271-6. DOI: 10.1046/j.1365-2362.1998.00289.x. View

16.

Barkan A, Marilus R, Winkelsberg G, Yeshurun D, Blum I . Primary hyperparathyroidism: possible cause of primary hyperaldosteronism in a 60-year-old woman. J Clin Endocrinol Metab. 1980; 51(1):144-7. DOI: 10.1210/jcem-51-1-144. View

17.

Redgrave J, Rabinowe S, Hollenberg N, Williams G . Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives. J Clin Invest. 1985; 75(4):1285-90. PMC: 425457. DOI: 10.1172/JCI111828. View

18.

Stefenelli T, Abela C, Frank H, Niederle B . Time course of regression of left ventricular hypertrophy after successful parathyroidectomy. Surgery. 1997; 121(2):157-61. DOI: 10.1016/s0039-6060(97)90285-3. View

19.

Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208-18. DOI: 10.1097/01.ASN.0000133041.27682.A2. View

20.

Jorde R, Sundsfjord J, Fitzgerald P, Bonaa K . Serum calcium and cardiovascular risk factors and diseases: the Tromsø study. Hypertension. 1999; 34(3):484-90. DOI: 10.1161/01.hyp.34.3.484. View